Nijmegen, August 19th, 2024 – TropIQ Health Sciences is pleased to announce the appointment of Michiel van Alst as the new Chief Executive Officer, effective September 1st, 2024. Michiel brings over 20 years of extensive experience in the Biomedical and Pharmaceutical B2B sectors, positioning him as an innovative leader who will guide TropIQ into its next chapter of growth and innovation.
With a strong background in driving business success in the life sciences industry, Michiel is set to lead TropIQ as the company continues to expand its pioneering research and services in vector-borne diseases. A key focus under his leadership will be the increased adoption of One Health approaches, integrating human, animal, and environmental health strategies to combat diseases like malaria more effectively.
Michiel van Alst succeeds Koen Dechering, who has been at the helm of TropIQ since its foundation. Koen will transition into the role of Vice President of Business Development, where he will continue to play a vital role in building strategic partnerships and accelerating client R&D programs.
Michiel van Alst commented on his new role:
“I am truly honored to join this remarkable company, which is dedicated to the eradication of deadly diseases like malaria. What inspires me most is the unwavering commitment of the team, the powerful mission that drives our work, and the cutting-edge technologies we provide to our clients. TropIQ embodies the spirit of purpose-driven innovation and I am proud to be able to contribute to this further.”
Koen Dechering also shared his thoughts on the leadership transition:
“As a co-founder and CEO for the past 13 years, I am delighted that Michiel has accepted the role of leading TropIQ into its next phase. Michiel’s experience and proven track record align exceptionally well with TropIQ’s ambitions for the coming years. My own role will continue to focus on building partnerships, exploring business opportunities, and helping our clients accelerate their R&D programs. I am excited to work with Michiel to increase the impact of our company.”
Under Michiel’s leadership, TropIQ will continue to leverage its innovative capabilities to address global health challenges, enhancing its position as a leader in vector-borne disease research and services.
About TropIQ Health Sciences
TropIQ Health Sciences, spin-off of Radboud University Medical Center, is a leading company in vector-borne disease research, committed to developing cutting-edge solutions to combat diseases like malaria. The company combines expertise in biology, chemistry, and data science to offer innovative research services and technologies to clients worldwide. With a strong emphasis on the One Health approach, TropIQ is dedicated to improving global health outcomes through collaboration and innovation.